Jennifer a Cafardi the Manual of Dermatology 2012

Total Page:16

File Type:pdf, Size:1020Kb

Jennifer a Cafardi the Manual of Dermatology 2012 The Manual of Dermatology Jennifer A. Cafardi The Manual of Dermatology Jennifer A. Cafardi, MD, FAAD Assistant Professor of Dermatology University of Alabama at Birmingham Birmingham, Alabama, USA [email protected] ISBN 978-1-4614-0937-3 e-ISBN 978-1-4614-0938-0 DOI 10.1007/978-1-4614-0938-0 Springer New York Dordrecht Heidelberg London Library of Congress Control Number: 2011940426 © Springer Science+Business Media, LLC 2012 All rights reserved. This work may not be translated or copied in whole or in part without the written permission of the publisher (Springer Science+Business Media, LLC, 233 Spring Street, New York, NY 10013, USA), except for brief excerpts in connection with reviews or scholarly analysis. Use in connection with any form of information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed is forbidden. The use in this publication of trade names, trademarks, service marks, and similar terms, even if they are not identifi ed as such, is not to be taken as an expression of opinion as to whether or not they are subject to proprietary rights. While the advice and information in this book are believed to be true and accurate at the date of going to press, neither the authors nor the editors nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein. Printed on acid-free paper Springer is part of Springer Science+Business Media (www.springer.com) Notice Dermatology is an evolving fi eld of medicine. Research and clinical experience continue to broaden our approach to illnesses, therapies and our general approach to disease. Readers are advised to check the most current product information avail- able, which is provided by the manufacturer of each medication and device to verify dosages, duration of administration and contraindications. Although every effort has been made to give the most up to date and clinically relevant material, it is the responsibility of the treating physician, relying on experience and knowledge of the patient, to determine the dosages and treatment plans best suited to the individual patient. The author of this book assumes no liability for any injury and/or damage to persons or property arising from this publication. v Contents Notice ................................................................................................................ v The Manual Dermatology .............................................................................. 1 Coding .......................................................................................................... 1 Hair Disorders .............................................................................................. 15 Nail Disorders .............................................................................................. 65 Pediatric Dermatology ................................................................................. 83 Procedural Dermatology .............................................................................. 155 Med Toxicity Monitoring ............................................................................. 165 General Derm ............................................................................................... 205 Index ................................................................................................................. 549 vii List of Abbreviations 5-FU 5-Fluorouracil 5-HIAA 5-Hydroxyindole acetic acid AA Alopecia areata ABX Antibiotics ACC Aplasia cutis congenita ACTH Adrenocorticotropic hormone AD Autosomal dominant AE Adverse events AFX Atypical fi broxanthoma AGEP Acute generalized exanthematous pustulosis AK Actinic keratosis AKN Acne keloidalis nuchae ALA Aminolevulinic acid ALT Alanine transaminase AN Acanthosis nigricans ANA Antinuclear antigen AR Autosomal recessive ASLO Antistreptolysin O AZA Azathioprine BCC Basal cell carcinoma BP Bullous pemphigoid BSLE Bullous systemic lupus erythematosus CAH Congenital adrenal hyperplasia CARP Confl uent and reticulated papillomatosis CCB Calcium channel blockers CCCA Central centrifugal cicatricial alopecia CLL Chronic lymphocytic leukemia CMTC Cutis marmorata telangiectatica congentia CNH Chondrodermatitis nodularis helices CP Cicatricial pemphigoid CTCL Cutaneous T-cell lymphoma CTD Connective tissue disease CVD Cardiovascular disease CXR Chest x-ray ix x List of Abbreviations DDx Differential diagnosis DFA Direct fl uorescent antibody DFSP Dermatofi brosarcoma protuberans DH Dermatitis herpetiformis DHEA-S Dehydroepiandrosterone sulfate DHT Dihydrotestosterone DIC Disseminated intravascular coagulation DIF Direct immunofl uorescence DIRA Defi ciency of the interleukin-1-receptor DLE Discoid lupus erythematosus (also known as chronic cutaneous lupus erythematosus ) DLSO Distal lateral subungal onychomycosis DM Dermatomyositis or diabetes mellitus (depending on context) DRESS Drug rash with eosinophilia and systemic symptoms dz Disease E&M Evaluation and management EAC Erythema annulare centrifugum EB Epidermolysis bullosa EBA Epidermolysis bullosa acquisita ED&C Electrodessication and curretage EDP Erythema dyschromicum perstans EDV Epidermodysplasia verruciformis EED Erythema elevatum diutinum EGFR Epidermal growth factor receptor EM Electron microscopy or Erythema multiforme (depending on context) EN Erythema nodosum EPS Elastosis perforans serpiginosa ESR Erythrocyte sedimentation rate ESRD Endstage renal disease ETOH Ethanol FCAS Familial cold auto-infl ammatory syndrome FFA Frontal fi brosing alopecia FH Family history FMF Familial mediterranean fever G6PD Glucose-6-phosphate dehydrogenase GA Granuloma annulare GFR Glomerular fi ltrate rate GI Gastrointestinal GVHD Graft versus host disease HA Headache HAIR-AN Hyperandrogenism (HA), insulin resistance (IR) and acanthosis nigricans (AN) HCTZ Hydrochlorothiazide HIV Human immunodefi ciency virus HPV Human papillomavirus List of Abbreviations xi HS Hidradenitis suppurativa HSM Hepatosplenomegaly HSP Henoch-schönlein purpura HSV Herpes simplex virus HTN Hypertension Hx History HZ Herpes zoster I&D Incision and drainage IFN Interferon IIF Indirect immunofl uorescence IL Intralesional or interleukin (depending on context) INH Isoniazid IP Incontinentia pigmenti IPL Intense pulsed light IVIG Intravenous immunoglobulin JAAD Journal of the American academy of dermatology JXG Juvenile xanthogranuloma KD Kawasaki disease KOH Potassium hydroxide KS Kaposi’s sarcoma LABD Linear IgA bullous dermatosis LCH Langerhans cell histiocytosis LCV Leukocytoclastic vasculitis LFT Liver function tests LN Lymphadenopathy LP Lichen planus LPP Lichen planopilaris LR Livedo reticularis LsA Lichen sclerosus et atrophicus MAL Methyl aminolevulinate MCC Merkel cell carcinoma MF Mycosis fungoides MMF Mycophenolate mofetil MPS Mucopolysaccharidoses MR Mental retardation MSM Men who have sex with men MTX Methotrexate NASH Nonalcoholic steatohepatitis NbUVB Narrowband UVB NF Neurofi bromatosis NICH Noninvoluting congenital hemangioma NI Normal NL Necrobiosis lipoidica (previously called Necrobiosis lipoidica diabeticorum) NSF Nephrogenic systemic fi brosis xii List of Abbreviations OCPs Oral contraceptives PAPA Pyogenic arthritis, pyoderma gangrenosum and acne syndrome PASI Psoriasis area and severity index PCN Penicillin PCOS Polycystic ovarian syndrome PCP Pneumocystis pneumonia PCR Polymerase chain reaction PCT Porphyria cutanea tarda PDL Pulsed dye laser PDT Photodynamic therapy PF Pemphigus foliaceous PFB Pseudofolliculitis barbae PG Pyoderma gangrenosum or pyogenic granuloma (depends on context) PHACES Posterior fossa, hemangioma, arterial lesions, coarctation of aorta & cardiac anomalies, eye abnormalities and sternal clefting/ supraumbilical abdominal raphe PLC Pityriasis lichenoides chronica PLEVA Pityriasis lichenoides et varioliformis acuta PMH Past medical history PMLE Polymorphous light eruption PNP Paraneoplastic pemphigus PO By mouth POD Perioral dermatitis POEMS Polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes PPK Palmar plantar keratoderma PPV Phakomatosis pigmentovascularis PR Pityriasis rosea PRP Pityriasis rubra pilaris PSA Prostate-specifi ca antigen PSO Proximal subungal onychomycosis Pt Patient PT Pili torti PUD Peptic ulcer disease PUPPP Pruritic urticarial papules and plaques of pregnancy PUVA Psoralen + UVA PV Pemphigus vulgaris RA Rheumatoid arthritis RAS Recurrent aphthous stomatitis RAST Radioallergosorbent test RICH Rapidly involuting congenital hemangioma ROM Range of motion ROS Review of systems RPC Reactive perforating collagenosis RPR Rapid plasma reagin List of Abbreviations xiii Rx Prescription SAHA Seborrhoea, acne, hirsutism and alopecia SCC Squamous cell carcinoma SCLE Subacute cutaneous lupus erythematosus SH Social history SHBG Sex hormone binding globulin SJS Stevens Johnson syndrome SK Seborrheic keratosis SLE Systemic lupus erythematosus soln Solution SSRI Selective serotonin reuptake inhibitor SSSS Staphylococcal scalded skin syndrome TCA Trichloroacetic acid TCN Tetracycline TEN Toxic epidermal necrolysis TLR Toll-like receptor TMEP Telangiectasia macularis eruptiva perstans TMP-SMX Trimethoprim-sulfamethoxazole TN Trichorrhexis nodosa TNF Tumor necrosis factor tPA Tissue plasminogen activator TPMT Thiopurine methyltransferase TRAPS Tumor necrosis factor associated receptor syndromes TSH Thyroid stimulating hormone
Recommended publications
  • Review Article Pruritus in Systemic Diseases: a Review of Etiological Factors and New Treatment Modalities
    Hindawi Publishing Corporation e Scientific World Journal Volume 2015, Article ID 803752, 8 pages http://dx.doi.org/10.1155/2015/803752 Review Article Pruritus in Systemic Diseases: A Review of Etiological Factors and New Treatment Modalities Nagihan Tarikci, Emek Kocatürk, Fule Güngör, IlteriG OLuz Topal, Pelin Ülkümen Can, and Ralfi Singer Department of Dermatology, Okmeydanı Training and Research Hospital, 34384 Istanbul, Turkey Correspondence should be addressed to Emek Kocaturk;¨ [email protected] Received 20 February 2015; Revised 11 June 2015; Accepted 16 June 2015 Academic Editor: Uwe Wollina Copyright © 2015 Nagihan Tarikci et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Pruritus is the most frequently described symptom in dermatology and can significantly impair the patient’s quality of life. In 10–50% of adults with persistent pruritus, it can be an important dermatologic clue for the presence of a significant underlying systemic disease such as renal insufficiency, cholestasis, hematologic disorder, or malignancy (Etter and Myers, 2002; Zirwas and Seraly, 2001). This review describes the presence of pruritus in different systemic diseases. It is quite important to discover the cause of pruritus for providing relief for the patients experiencing substantial morbidity caused by this condition. 1. Pruritus Endocrinal Disorders. Thyroid diseases, diabetes mellitus. Pruritus is a topic that has caused a great deal of controversy Paraneoplastic Diseases. Lymphomas and solid organ tumors. because it is difficult to characterize and define. Various indirect definitions proposed include a sensation which provokes the desire to scratch or an uneasy sensation of 2.
    [Show full text]
  • 2U11/13U195 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date Χ n n 20 October 2011 (20.10.2011) 2U11/13U195 Al (51) International Patent Classification: ka Pharmaceutical Co., Ltd., 1-7-1, Dosho-machi, Chuo- C12P 19/34 (2006.01) C07H 21/04 (2006.01) ku, Osaka-shi, Osaka 541-0045 (JP). (21) International Application Number: (74) Agents: KELLOGG, Rosemary et al; Swanson & PCT/US201 1/032017 Bratschun, L.L.C., 8210 SouthPark Terrace, Littleton, Colorado 80120 (US). (22) International Filing Date: 12 April 201 1 (12.04.201 1) (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, English (25) Filing Language: AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, (26) Publication Language: English CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (30) Priority Data: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, 61/323,145 12 April 2010 (12.04.2010) US KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, (71) Applicants (for all designated States except US): SOMA- ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, LOGIC, INC. [US/US]; 2945 Wilderness Place, Boulder, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, Colorado 80301 (US). OTSUKA PHARMACEUTI¬ SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, CAL CO., LTD.
    [Show full text]
  • Report from the Inaugural Australian Pruritus Symposium, Sydney, Australia, August 10, 2013
    Acta Derm Venereol 2014; 94: 123 LETTER TO THE EDITOR Report from the Inaugural Australian Pruritus Symposium, Sydney, Australia, August 10, 2013 Frank Brennan1 and Dedee F. Murrell2* 1Palliative Medicine, Calvary Hospital, 91 Rocky Point Road, and 2Department of Dermatology, St George Hospital, University of New South Wales, Gray St, Kogarah, Sydney, NSW 2217 Australia. *E-mail: [email protected] Accepted Aug 28, 2013; Epub ahead of print Oct 24, 2013 Sir, on the mechanisms and management of opioid-induced The inaugural Australian symposium on pruritus was itch. Frank Brennan spoke on uraemic pruritus, Paul Gray, convened at St George Hospital, Sydney on August 10, a Pain Specialist with a particular interest in burns spoke 2013. The co-conveners were Professor Dedee Murrell, on the phenomenon of post-burns pruritus and Craig Le- Executive Vice President of the International Society of wis, Medical Oncologist surveyed the symptom of itch Dermatology (ISD) and Dr Frank Brennan, Palliative and its management in cancer medicine. Medicine Physician. The impetus behind the symposium A feature of the day was an interview with a patient was the recognition of two facts. Firstly, the significant in front of the symposium participants. The patient developments in the understanding of the pathophysio- presented with a challenging combination of pruritus logy of pruritus in recent years and, secondly, the paucity secondary to a life-long history of atopy and, in later of education and understanding by colleagues across years, uraemic pruritus. Connie Katelaris surveyed the multiple disciplines of those developments. Given that history and immunological results of the patient and the symptom of pruritus manifests in many diseases the made clinical recommendations.
    [Show full text]
  • Primary Follicular Mucinosis
    International Journal of Scientific & Engineering Research Volume 8, Issue 6, June-2017 1303 ISSN 2229-5518 Case Report Primary Follicular Mucinosis: A Case Report From Saudi Arabia With Successful Treatment And Literature Review SalaimanAlsaiari1 AwadhAlAmri2 AmerAlmuqati Ibrahim Allihibi ABSTRACT: Background:Follicular mucinosis is an uncommon inflammatory disorder that characteristically presents as clearly defined, erythematous plaques or papules, with follicular projections, superficial scaling, and alopecia in terminal hair bearing areas, characterized histologically by mucin accumulation in pilosebaceous units (follicular epithelium and sebaceous glands) . The condition is generally divided into primary (idiopathic) and secondary forms in association with several conditions including benign and malignant diseases. There are many local and systemic treatments. Main observations: We report a case of 15 years old male with primary follicular mucinosis treated effectively by intralesional steroid injections. Conclusions: This is a new case of Primary follicular mucinosis from Saudi Arabia was treated successfully with intralesional corticosteroids without relapse. KEYWORDS:follicular mucinosis, intralesional corticosteroids, treatment. —————————— —————————— INTRODUCTIONIJSER Follicular mucinosis is a rare condition, of unknown cause, which affects all races, ages and both sexes.1,2It is defined as the accumulation of mucin in the follicular epithelium and sebaceous glands.3,5 It was initially described in 1957 by Pinkus who named it
    [Show full text]
  • Dermatology Volume 58 Issue 2 March-April 2013 Indian Journal Of
    Indian Journal of ISSN: 0019-5154 Dermatology Volume 58 Issue 2 March-April 2013 Indian Journal of Highlights of the issue Dermatology • Update on cutaneous calciphylaxis • Macrophage migration inhibitory factor in • V Dermatology olume • Fixed duration therapy in leprosy 58 • Issue • Environmental dermatoses in Ladakh • Demodex folliculorum as a risk factor in 2 • Diagnosing rosacea March-April • Annular lesions in Dermatology 2013 • Pages Clinical and photomicrograph of Mycosis fungoides, PET-CT for staging and response assessment IJD® Symposium: Integrative Dermatology 87-**** Guest Editor: S R Narahari IJD® www.e-ijd.org E‑Case Report Angiolymphoid Hyperplasia with Eosinophilia with Follicular Mucinosis Rameshwar Gutte, Bhavana Doshi, Uday Khopkar From the Department of Dermatology, Seth G. S. Medical College and King Edward Memorial Hospital, Mumbai, India Abstract Follicular mucinosis occurring along with angiolymphoid hyperplasia with eosinophils (ALHE) has been described in a 49-year-old male. The patient presented with pruritic hyperpigmented papules and nodules on the vertex and right parietal scalp. There was no any other complaint. Histopathological examination from one of the papule showed prominent blood vessels in the dermis lined by plump histiocytoid endothelial cells that were surrounded by a dense lymphoid infiltrate with numerous eosinophils; these findings are typical of angiolymphoid hyperplasia with eosinophilia. Features of follicular mucinosis were observed in the same section with 3 hyperplastic follicular infundibula containing pools of mucin in the infundibular epithelium. The concurrent occurrence of these 2 distinct histopathological patterns in the same biopsy specimen has been reported rarely. Key Words: Angiolymphoid hyperplasia, eosinophilia, follicular mucinosis, scalp What was known? perivascular area and other parts of the dermis.
    [Show full text]
  • Acne Keloidalis Nuchae
    Dermatologic Therapy, Vol. 20, 2007, 128–132 Copyright © Blackwell Publishing, Inc., 2007 Printed in the United States · All rights reserved DERMATOLOGIC THERAPY ISSN 1396-0296 Blackwell Publishing Inc Acne keloidalis nuchae Acne keloidalis nuchae, also known as folliculitis its antimicrobial and antiinflammatory effect), nuchae, is a chronic scarring folliculitis charac- and a series of intralesional steroids (40 mg/cc of terized by fibrotic papules and nodules of the existing keloids). Education is the key to preven- nape of the neck and the occiput. It particularly tion. I discourage high-collared shirts, short hair- affects young men of African descent and rarely cuts, and close shaving or cutting the hair along occurs in women; in either case its occurrence the posterior hairline. In the long-term, patients has a significant impact on the patient’s quality benefit from laser hair removal using diode or of life. We’ve asked our experts to share their expe- Nd:YAG, which helps avoid disease progression. rience in helping patients with this cosmetically Early treatment decreases the morbidity that can disfiguring disorder. be associated with late-stage disease. Question Dr. Vause: I treat early acne keloidalis nuchae by instructing patients to wash the skin frequently Please describe your approach to the treatment of with a mild keratolytic like tar or an alpha hydroxy patients with early (less than 20 papules, pustules acid cleanser. Patients are instructed to apply and 1–2 < 2 cm nuchae keloids) acne keloidalis topical clindamycin with steroid in the morning nuchae. (1–3) and retinoid at bedtime. Dr. Brauner: An option is to treat all patients with Response chlorhexadine cleanser as a daily shampoo and minocycline 100 mg daily b.i.d.
    [Show full text]
  • 15. Dermatology Eponyms
    Dermatology Eponyms DERMATOLOGY EPONYMS – PHENOMEN / SIGN – LEXICON (D) Brzeziński Piotr1, Wollina Uwe2, Poklękowska Katarzyna3, Khamesipour Ali4, Herrero Gonzalez Jose Eugenio5, Bimbi Cesar6, Di Lernia Vito7, Karwan Krzysztof 8 16th Military Support Unit, Ustka, Poland. [email protected] 2Department of Dermatology & Allergology, Hospital Dresden-Friedrichstadt, Academic Teaching Hospital of the Technical University of Dresden, Dresden, Germany [email protected] 3Mazowiecki Branch of the National Health Fund, Warsaw, Poland [email protected] 4Center for Research and Training in Skin Diseases and Leprosy, Tehran University of Medical Sciences, Tehran, Iran [email protected] 5Malalties Ampul.lars i Porfíries, Departament de Dermatologia, Hospital del Mar, Barcelona, Spain [email protected] 6Brazilian Society of Dermatology [email protected] 7Department of Dermatology, Arcispedale Santa Maria Nuova, Reggio Emilia, Italy [email protected] 8The Emergency Department, Military Institute of Medicine, Warsaw, Poland [email protected] N Dermatol Online. 2011; 2(3): 158-170 Date of submission: 08.04.2011 / acceptance: 29.05.2011 Conflicts of interest: None DANIELSSEN’S SIGN Anesthetic leprosy. A form of leprosy chiefly affecting the nerves, marked by hyperesthesia succeeded by anesthesia, and by paralysis, ulceration, and various trophic disturbances, terminating in gangrene and mutilation. In 1895 I presented to the Ohio State Medical Society two sisters, natives of Ohio, who manifested appearances of anesthetic leprosy. Synonyms: Danielssen disease, Danielssen-Boeck disease, dry leprosy, trophoneurotic leprosy. OBJAW DANIELSSENA Anesthetic leprosy. Postać trądu głównie wpływająca na nerwy, początkowo charakteryzuje się oznaczone przeczulicą, następcą znieczulicą i paraliŜem, owrzodzeniem i róŜnymi zaburzeniami troficznymi, kończąca się w gangreną i okaleczeniem. W 1895 roku przedstawiono w Ohio State Medical Society dwie siostry z Ohio, u których występowały objawy anesthetic Figure 1.
    [Show full text]
  • Impact of Photostability and UVA/UVA-Blue Light Protection On
    Thannhausen, Germany, August 06, 2019 Thannhausen, Germany, | Volume 145 Volume | 7+8/19 powered by skin whitening Natural Extremolyte Fights Pigmentation Caused by Environmental Stressors 7/8 Impact of Photostability 2019 english solubilizers Effective Natural Alternatives to Synthetic Solubilizers – a Comparison Study sun care and UVA/UVA-Blue Light Impact of Photostability and UVA/UVA-Blue Light Protection on Free Radical Generation Blue Light Induced Hyperpigmentation in Skin and How to Prevent it Photostabilisation: The Key to Robust, Protection on Free Radical Safe and Elegant Sunscreens disinfection Skin and Environmentally Safe and Universally Useable Disinfectant for all Generation Surfaces with Green Technology skin/hair care Natural Oil Metathesis Unveils High-Performance Weightless Cosmetic Emollients M. Sohn, S. Krus, K. Jung, M. Seifert, M. Schnyder SOFW Journal 7+8/19 | Volume 145 | Thannhausen, Germany, August 06, 2019 personal care | sun care Impact of Photostability and UVA/UVA-Blue Light Protection on Free Radical Generation M. Sohn, S. Krus, K. Jung, M. Seifert, M. Schnyder abstract he impact of UV-filter combination on the number of free radicals generated in sunscreen formulations and the skin follow- Ting UV-VIS irradiation was assessed via electron spin resonance spectroscopy using a spin-probing approach. Four UV-filter combinations that differed in their photostability and range of UVA absorbance coverage were investigated. Fewer free radicals were generated in the sunscreen formulation when a photostable UVA filter system was used, compared to a stabilized UVA fil- ter system. Additionally, fewer free radicals were generated in the skin when a sunscreen with long UVA protection extending to the short visible range was used, compared to a sunscreen with minimal UVA protection.
    [Show full text]
  • Dr. Keesha Ewers Foreword by Dr
    The Woman’s Guide to Reclaiming Emotional Freedom and Vibrant Health Dr. Keesha Ewers Foreword by Dr. Tom O’Bryan www.DrKeesha.com • Solving the Autoimmune Puzzle 1 Bestselling Author of The Autoimmune Fix and the Betrayal Docuseries Praise for Solving the Autoimmune Puzzle “Solving the Autoimmune Puzzle is functional medicine at its best. Dr. Keesha Ewers integrates her wealth of knowledge from behavioral science, Ayurve- dic medicine, and functional medicine to create an easy to use system that gets to the core of real healing. This book is full of practical information and tools that will free all who use it from pain and suffering of any kind, including autoimmune disease.” —Dr. Mark Hyman, New York Times bestselling author of Eat Fat, Get Thin. Director, Cleveland Clinic Center for Functional Medicine. “I applaud Dr. Ewers for bringing to light two very often overlooked root causes for those suffering with autoimmunity: stress and trauma. In her book, Solving the Autoimmune Puzzle: The Woman’s Guide to Reclaiming Emotional Freedom and Vibrant Health, Dr. Ewers dives deep into emotional aspects of those with autoimmunity and shows the reader how to come to peace with themselves and their trauma allowing them to heal from autoimmunity.” —Amy Myers, MD, New York Times bestselling author of The Autoimmune Solution and The Thyroid Connection. “Dr. Keesha Ewers lays out a clear, easy-to-follow roadmap to break free from inflammation and autoimmune disease. Her insightful, well-researched plan uncovers the missing pieces of the autoimmune puzzle and shows how to reverse this century’s greatest health challenge for women.” —JJ Virgin, CNS, CHFS, NYT bestselling author of The Virgin Diet & Sugar Impact Diet “Solving the Autoimmune Puzzle provides you with a straight forward way to understand the root causes of complex diseases of all kinds, including auto- immunity.
    [Show full text]
  • Integrative Approach to a Difficult Trichology Patient Natalie Barunova* International Scientific-Practical Centre “Trichology”, Moscow, Russia
    Global Dermatology Clinical Case ISSN: 2056-7863 Integrative approach to a difficult trichology patient Natalie Barunova* International Scientific-Practical Centre “Trichology”, Moscow, Russia Abstract Folliculitis decalvans belongs to a group of primary cicatricial alopecias with neutrophilic inflammation of the scalp. It is characterized by recurrent purulent follicular exudation with inevitable destruction of pilosebaceous unit as an outcome of the disease. Staphylococcus aureus is supposed to play an important role in the pathogenesis of the disease. The treatment is usually focused on the eradication of S. aureus. A clinical case of effective adjuvant treatment of folliculitis decalvans patient is presented in this manuscript. The previous traditional treatment with antibiotics, topical glucocorticosteroids, oral prednisone and retinoid treatment had minor efficacy and subsequent recurrence. Integrative approach to this difficult case brought the patient into remission and improve the patient’s condition. Introduction alopecias, such as dissecting cellulites, lichen planopilaris, discoid lupus erythematosus, central centrifugal cicatricial alopecia and acne Scarring alopecias relate to a group of relatively rare diseases with keloidalis nuchae [2,7-9]. one common feature - inevitable destruction of pilosebaceous unit due to replacement of hair follicles by fibrous tissue. Differential diagnosis is performed with the following conditions [2,10]: FD is classified as a primary neutrophilic scarring alopecia according to the classification from the 2001 Workshop on cicatricial • Dissecting folliculitis – occurs almost exclusively in males. alopecias at Duke University Medical Center [1]. Clinical features include boggy scalp, deep inflammatory nodes, interconnected sinus tracts with purulent material; It is characterized by recurrent purulent follicular exudation with patches of scarring (cicatricial) alopecia as an outcome of the condition • Acne keloidalis nuchae – also occurs mainly in males and low efficacy of the treatment.
    [Show full text]
  • Mineral Makeup and Its Role with Acne and Rosacea Jane Iredale, MA; Jennifer Linder, MD
    REVIEW Mineral Makeup and Its Role With Acne and Rosacea Jane Iredale, MA; Jennifer Linder, MD Rosacea and acne have been the cause of physical and emotional distress for patients worldwide. Part of the distress has originated from the inability to find products that provide coverage without exacerbating the conditions. This includes understanding the role of certain ingredients with their attendant negative and positive effects. Fifteen years of experience has shown that mineral makeup can play a large part in helping to repair patients’ self-esteem as well as playing a meaningful role in skin improvement. IDENTIFYING AUTHENTIC For physicians to assess mineral makeup and its ben- MINERAL MAKEUP efits for their patients with rosacea and acne, it is neces- Patients with acne and rosacea frequently seek options to sary to explore the chemical composition of authentic cover what they consider toCOS be visually frustrating condi- DERMmineral powder. Many makeup brands are now mar- tions. Regrettably, they often make choices that are not keting products they call mineral makeup, but they effective and potentially detrimental to their situation. do not utilize authentic minerals in their formulations. To serve these patients better, physicians should educate The incorrect use of the word mineral as a marketing themselves and their staffs about camouflaging options. term confuses patients and can lead to the use of prod- Mineral makeup can beDo a satisfactory solutionNot as it is a ucts Copythat can potentially worsen their condition due to healthy, skin-friendly alternative to traditional makeup. problematic ingredients. Mineral makeup not only provides superior coverage and The original definition of mineral makeup is a makeup is easy to use, but it is also UV protective, noncomedo- that eliminates talc, potential skin irritants, and comedo- genic, and anti-inflammatory.
    [Show full text]
  • United States Patent (19) 11 Patent Number: 5,994,330 El Khoury (45) Date of Patent: Nov.30, 1999
    USOO599433OA United States Patent (19) 11 Patent Number: 5,994,330 El Khoury (45) Date of Patent: Nov.30, 1999 54 TOPICAL APPLICATION OF MUSCARINIC S. Abram, MD et al., Anesth Analg., “Intrathecal Acetyl AGENTS SUCH AS NEOSTIGMNE FOR Cholinesterase Inhibitors Produce Analgesia That is Syner TREATMENT OF ACNE AND OTHER gistic with Morphine and Clonidine in Rats, 81:501-7 NFLAMMATORY CONDITIONS (1995). C. Stein, M.D. et al., New England Journal of Medicine, vol. 76 Inventor: Georges F. El Khoury, 1561 Ramillo 325, No. 16 “Analgesic Effect of Intraarticular Morphine Ave., Long Beach, Calif. 90815 After Arthroscopic Knee Surgery, pp. 1123-1126. T. Yaksh, Ph.D. et al., Anesthesiology, “Studies on the Safety 21 Appl. No.: 09/188,328 of Chronically Administered Intrathecal Neostigmine Meth 22 Filed: Nov. 9, 1998 ylsulfate in Rats and Dogs,” V 82. No. 2, Feb. 1995. “Morphine-A Local Analgesic, International ASSocia (51) Int. Cl." ..................................................... A01N 57/00 tion for the Study of Pain, vol. III. 52 U.S. Cl. .......................... 514/123; 514/123; 514/859; G. Lauretti, MD et al., Anesth Analg “The Effects of 514/855; 514/289; 514/912; 514/78.04; Intrathecal Neostigmine on Somatic and Visceral Pain: 424/401 Improvement by Associate with a Peripheral Anticholin 58 Field of Search ........................... 424/401; 536/55.1; ergic,” 81:615–20 (1996). 514/912, 78.04, 289, 859, 123,855 D. Hood, M.D., et al., Anesthesiology, “Phase I Safety Assessment of Intrathecal Neostigmine Methylsulfate in 56) References Cited Humans,” V 82, No. 2, Feb. 1995 pp. 331-342. U.S.
    [Show full text]